These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11056493)

  • 1. Exploitable mechanisms for the blockade of androgenic action.
    Griffiths K; Denis LJ
    Prostate Suppl; 2000; 10():43-51. PubMed ID: 11056493
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
    Bostwick DG
    Anat Pathol; 1998; 3():1-16. PubMed ID: 10389579
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
    Carroll PR; Kantoff PW; Balk SP; Brown MA; D'amico AV; George DJ; Grossfeld GD; Johnson CS; Kelly WK; Klotz L; Lee WR; Lubeck DP; Mcleod DG; Oh WK; Pollack A; Sartor O; Smith MR; Hart C;
    Urology; 2002 Sep; 60(3 Suppl 1):1-6. PubMed ID: 12231036
    [No Abstract]   [Full Text] [Related]  

  • 4. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy.
    Bostwick DG; Ramnani D; Cheng L
    Urol Clin North Am; 1999 Aug; 26(3):465-79. PubMed ID: 10494285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal manipulation for rising PSA after radical prostatectomy.
    Bhayani SB; Andriole GL
    Semin Urol Oncol; 1999 Aug; 17(3):148-53. PubMed ID: 10462318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hormonal treatments of prostate cancer].
    Kuhn JM
    Rev Prat; 1990 Nov; 40(25):2357-62. PubMed ID: 2124721
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
    Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
    Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer prevention trial yields positive results, but with a few cautions.
    Reynolds T
    J Natl Cancer Inst; 2003 Jul; 95(14):1030-1. PubMed ID: 12865442
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on the appropriateness of The Prostate publishing a trial comparing Permixon to finasteride without a placebo control group.
    Gillenwater JY
    Prostate; 1998 Nov; 37(3):194. PubMed ID: 9792137
    [No Abstract]   [Full Text] [Related]  

  • 12. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
    Wang LG; Mencher SK; McCarron JP; Ferrari AC
    Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
    Griffiths K; Morton MS; Nicholson RI
    Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
    Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
    Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy of prostate cancer.
    Bare RL; Torti FM
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of finasteride and bicalutamide on prostatic blood flow in the rat.
    Lekås E; Bergh A; Damber JE
    BJU Int; 2000 May; 85(7):962-5. PubMed ID: 10792183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 18. The future of prostate cancer prevention.
    Brawley OW; Barnes S; Parnes H
    Ann N Y Acad Sci; 2001 Dec; 952():145-52. PubMed ID: 11795434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
    Unlühizarci K K; Everest H; Bayram F; Keleştimur F
    Fertil Steril; 2002 Dec; 78(6):1331-3. PubMed ID: 12477537
    [No Abstract]   [Full Text] [Related]  

  • 20. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.